JAK-3 SCID gene therapy

Drug Profile

JAK-3 SCID gene therapy

Alternative Names: SCID gene therapy; SCID JAK-3 gene therapy

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Gene therapies
  • Mechanism of Action Lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Immunological disorders

Most Recent Events

  • 02 Feb 2017 Discontinued - Phase-I for Immunological disorders in USA (Parenteral)
  • 27 Aug 2003 A preclinical study has been added to the Immunological disorders pharmacodynamics section
  • 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Immunological disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top